NewsBenzingaIDEAYA Biosciences: utile per azione del terzo trimestre di $(1,22) non raggiunge la stima di $(1,18), ricavi a $10,242 milioni superano la stima di $6,857 milioni IDEAYA Biosciences: utile per azione del terzo trimestre di $(1,22) non raggiunge la stima di $(1,18), ricavi a $10,242 milioni superano la stima di $6,857 milioni Benzinga 2026.11.03 11:15 (GMT+0) Open on Benzinga Other news Barclays Maintains Equal-Weight on Coca-Cola Femsa SAB de, Raises Price Target to $125 Barclays Maintains Underweight on Church & Dwight Co, Raises Price Target to $89 Barclays Maintains Underweight on Choice Hotels Intl, Raises Price Target to $107 Barclays Maintains Equal-Weight on Check Point Software Tech, Raises Price Target to $155 Argus Research Maintains Buy on Apple, Raises Price Target to $400 Archer-Daniels-Midland Expects 2027 Earnings To Be "Somewhere In The Range Of What 2026 Was, Plus/Minus A Little Bit"
Archer-Daniels-Midland Expects 2027 Earnings To Be "Somewhere In The Range Of What 2026 Was, Plus/Minus A Little Bit"
